SCHEDULE: Vanguard Group Amends 13G, Reports 0% Stake in Arrowhead

The Vanguard Group filed an amended Schedule 13G for Arrowhead Pharmaceuticals Inc., reporting 0% beneficial ownership following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 9 to its Schedule 13G for Arrowhead Pharmaceuticals Inc. regarding its Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the class of Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately, and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over those securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily a procedural update regarding The Vanguard Group's internal reporting structure rather than a substantive change in investment position or outlook for Arrowhead Pharmaceuticals Inc.

Future Outlook

No forward-looking statements or guidance regarding Arrowhead Pharmaceuticals Inc.'s performance or The Vanguard Group's future investment strategy are provided in this filing.

Industry Context

StockSavvy.ai notes that such internal realignments and subsequent adjustments to beneficial ownership reporting are standard compliance procedures for large asset managers like The Vanguard Group, reflecting organizational changes rather than a change in investment thesis regarding Arrowhead Pharmaceuticals Inc. specifically.

Stakeholder Impact

• Shareholders of Arrowhead Pharmaceuticals Inc. will see a change in the reported beneficial ownership by The Vanguard Group, which is a procedural update due to an internal realignment rather than a direct divestment based on company performance. The underlying holdings may still exist under different Vanguard entities.
• The Vanguard Group's internal reporting structure has been updated for compliance purposes, with subsidiaries now reporting beneficial ownership separately.

Key Dates

Recommendation

The filing is a procedural update from The Vanguard Group regarding its beneficial ownership reporting due to an internal realignment, not a reflection of Arrowhead Pharmaceuticals Inc.'s performance or a strategic investment decision. As such, it provides no new information to warrant a change in investment recommendation for Arrowhead Pharmaceuticals Inc. A 'hold' recommendation is appropriate as there's no new fundamental data to alter an existing position.

Keywords

Arrowhead Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Adviser